Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316038 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| Lx-2931 SCHEMBL304963 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL304965 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL316870 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL20744228 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL304964 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL20744226 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL306099 | 0.86 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL4382659 | 0.86 | L3MBTL1 (0.33) | L3MBTL1 | |
| Lx-2931 SCHEMBL306100 | 0.86 | L3MBTL1 (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2090334-A2 | Imidazole based compounds, compositions comprising them and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | claimed |
| US-20090068180-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-03-12 | — | — | US | claimed |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-09-06 | — | — | US | claimed |
| EP-2090334-B1 | Imidazole based compounds, compositions comprising them and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8404732-B2 | Methods of treating ulcerative colitis | LEXICON PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130005775-A1 | METHODS OF TREATING ULCERATIVE COLITIS | LEXICON PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8093267-B2 | Methods of treating rheumatoid arthritis | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-7825150-B2 | Compositions and methods for treating immunological and inflammatory diseases and disorders | LEXICON PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100113530-A1 | S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA | LEXICON PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100076030-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS | LEXICON PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-7649098-B2 | Imidazole-based compounds, compositions comprising them and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-2090334-A2 | Imidazole based compounds, compositions comprising them and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090068180-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-03-12 | — | — | US | disclosed |
| WO-2007100617-A2 | IMIDAZOLE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-09-06 | — | — | US | disclosed |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-09-06 | — | — | US | disclosed |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113530-A1 | S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA | S1PR1, S1PR2, SPHK1 | L3MBTL1 1382/4885 |
| US-20090068180-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | ASAH2, SGMS1, SMPD1 | L3MBTL1 3610/4885 |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | TPMT, INMT, NFKBIA | L3MBTL1 4383/4885 |
| US-20100076030-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS | SSB, NFKBIA, MPO | L3MBTL1 4705/4885 |
| US-20130005775-A1 | METHODS OF TREATING ULCERATIVE COLITIS | SI, S1PR2, SPHK2 | L3MBTL1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.